Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone

Diabetes, Obesity and Metabolism

Volumn 19, Issue 5, 2017, Pages 721-728

  Terra, Steven G ^a   Focht, Kristen ^a   Davies, Melanie ^b   Frias, Juan ^c   Derosa, Giuseppe ^d   Darekar, Amanda ^e   Golm, Gregory ^f   Johnson, Jeremy ^f   Saur, Didier ^a   Lauring, Brett ^f   Dagogo Jack, Sam ^g  

^a PFIZER INC   (United States)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c NATIONAL RESEARCH INSTITUTE   (United States)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

ertugliflozin; monotherapy; SGLT2; type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ERTUGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; 5-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-1-HYDROXYMETHYL-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIOBESITY AGENT; FUSED HETEROCYCLIC RINGS; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC DIET; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FUNGAL GENITAL INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOVOLEMIA; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; POLYURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT FAILURE; URINARY TRACT INFECTION; WEIGHT REDUCTION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; EXERCISE; HYPERGLYCEMIA; IMMUNOLOGY; INCIDENCE; METABOLISM; MICROBIOLOGY; MUCOSAL IMMUNITY; MULTIMODALITY CANCER THERAPY; MYCOSES; OVERWEIGHT; REPRODUCTIVE TRACT INFECTIONS;

ANTI-OBESITY AGENTS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, DIABETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNITY, MUCOSAL; INCIDENCE; MALE; MEMBRANE TRANSPORT MODULATORS; MYCOSES; OVERWEIGHT; REPRODUCTIVE TRACT INFECTIONS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85013455452     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12888     Document Type: Article

References (22)

1. Scheen AJ. SGLT2 inhibitors: benefit/risk balance. Curr Diab Rep. 2016;16:92.
2. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495-502.
3. Mascitti V, Maurer TS, Robinson RP, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011;54:2952-2960.
4. Amin NB, Wang X, Jain SM, et al. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17:591-598.
5. Amin NB, Wang X, Mitchell JR, et al. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17:805-808.
6. American Diabetes Association. Executive summary: standards of medical care in diabetes – 2012. Diabetes Care. 2012;35(suppl 1):S4-S10.
7. Liang K, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre-post design. Sankhya: Indian J Stat, Ser B. 2000;62:134-48.
8. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
9. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 1996;46:1470.
10. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequatley controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-382.
11. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208-219.
12. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycaemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-2224.
13. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262-275.
14. Eldor R, Pratley R, Golm G, et al. Effect of ertugliflozin plus sitagliptin on glycaemic control vs. either treatment alone in subjects with T2DM inadequately controlled with metformin. American Diabetes Association, 76th Scientific Sessions; June 10–14, 2016; New Orleans, LA [Abstract 125-LB].
15. Lauring B, Eldor R, Liu J, et al. Efficacy and safety of ertugliflozin in subjects with T2DM inadequately controlled on the dual combination of metformin and sitagliptin: the VERTIS SITA2 trial. European Association for the Study of Diabetes (EASD) 52th EASD Annual Meeting; September 12–16, 2016; Munich, Germany [Abstract 181].
16. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411-419.
17. Kalra S, Singh V, Nagrale D. Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review. Adv Ther. 2016;33:1502-1518.
18. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587-597.
19. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-1380.
20. Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032-2038.
21. Peters AL, Buschur EO, Buse JB, et al. Euglycaemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687-1693.
22. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680-1686.